Trial Outcomes & Findings for Effect of NMN Supplementation on Organ System Biology (NCT NCT04571008)
NCT ID: NCT04571008
Last Updated: 2026-03-11
Results Overview
The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion after intervention period.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
56 participants
Primary outcome timeframe
After at least 16 weeks of treatment
Results posted on
2026-03-11
Participant Flow
56 participants met the inclusion criteria and were randomly assigned in a double-blind fashion to either placebo or NMN.
Participant milestones
| Measure |
Placebo
At least 16 weeks of placebo.
|
NMN Supplementation
At least 16 weeks of NMN.
|
|---|---|---|
|
Overall Study
STARTED
|
28
|
28
|
|
Overall Study
COMPLETED
|
20
|
20
|
|
Overall Study
NOT COMPLETED
|
8
|
8
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Effect of NMN Supplementation on Organ System Biology
Baseline characteristics by cohort
| Measure |
Total
n=40 Participants
Total of all reporting groups
|
Placebo
n=20 Participants
At least 16 weeks of placebo.
|
NMN Supplementation
n=20 Participants
At least 16 weeks of NMN.
|
|---|---|---|---|
|
Age, Continuous
|
61.9 years
STANDARD_DEVIATION 7.2 • n=18 Participants
|
61.2 years
STANDARD_DEVIATION 7.5 • n=9 Participants
|
62.7 years
STANDARD_DEVIATION 7.0 • n=9 Participants
|
|
Sex: Female, Male
Female
|
32 Participants
n=18 Participants
|
17 Participants
n=9 Participants
|
15 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=18 Participants
|
3 Participants
n=9 Participants
|
5 Participants
n=9 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=18 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=18 Participants
|
0 Participants
n=9 Participants
|
1 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=18 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=18 Participants
|
1 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
White
|
38 Participants
n=18 Participants
|
19 Participants
n=9 Participants
|
19 Participants
n=9 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=18 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=18 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=9 Participants
|
|
Muscle Insulin Sensitivity
|
464.4 (nmol/kg FFM/min) / (µU/mL)
STANDARD_DEVIATION 185.1 • n=18 Participants
|
422.8 (nmol/kg FFM/min) / (µU/mL)
STANDARD_DEVIATION 194.4 • n=9 Participants
|
506.0 (nmol/kg FFM/min) / (µU/mL)
STANDARD_DEVIATION 170.0 • n=9 Participants
|
|
3-Hour Glucose Under the Concentration Curve
|
359 mg/dLx3hr
STANDARD_DEVIATION 61.4 • n=18 Participants
|
372 mg/dLx3hr
STANDARD_DEVIATION 64 • n=9 Participants
|
347 mg/dLx3hr
STANDARD_DEVIATION 58 • n=9 Participants
|
PRIMARY outcome
Timeframe: After at least 16 weeks of treatmentThe outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion after intervention period.
Outcome measures
| Measure |
Placebo
n=20 Participants
At least 16 weeks of placebo.
|
NMN Supplementation
n=20 Participants
At least 16 weeks of NMN.
|
|---|---|---|
|
Change in Muscle Insulin Sensitivity
|
19.0 (nmol/kg FFM/min) / (µU/mL)
Standard Deviation 95.0
|
13.5 (nmol/kg FFM/min) / (µU/mL)
Standard Deviation 88.4
|
SECONDARY outcome
Timeframe: After at least 16 weeks of treatmentPopulation: One person in the placebo group did not complete their Oral Glucose Tolerance test at the post visit.
The outcome will be assessed during modified oral glucose tolerance test after the intervenion
Outcome measures
| Measure |
Placebo
n=19 Participants
At least 16 weeks of placebo.
|
NMN Supplementation
n=20 Participants
At least 16 weeks of NMN.
|
|---|---|---|
|
Changes in Glucose Tolerance
|
-9.0 mg/dLx3 Hr
Standard Deviation 38.0
|
14 mg/dLx3 Hr
Standard Deviation 42
|
Adverse Events
Placebo
Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths
NMN Supplementation
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Placebo
n=28 participants at risk
At least 16 weeks of placebo.
|
NMN Supplementation
n=28 participants at risk
At least 16 weeks of NMN.
|
|---|---|---|
|
Respiratory, thoracic and mediastinal disorders
Cold symptoms
|
14.3%
4/28 • Number of events 4 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
21.4%
6/28 • Number of events 7 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
|
Gastrointestinal disorders
Nausea/vomiting/diarrhea
|
17.9%
5/28 • Number of events 5 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
3.6%
1/28 • Number of events 1 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
|
Skin and subcutaneous tissue disorders
Bruising/hematoma
|
3.6%
1/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
10.7%
3/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
|
Nervous system disorders
Headache
|
3.6%
1/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
7.1%
2/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
|
Nervous system disorders
Dizziness/Blurred Vision
|
7.1%
2/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
0.00%
0/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
|
Skin and subcutaneous tissue disorders
Cold sore
|
0.00%
0/28 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
7.1%
2/28 • Number of events 3 • From enrollment until the end of follow up after 16 weeks of supplementation
We used the adverse events definitions defined by ClinicalTrials.gov
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place